Clinical Trials Browser

INDUSTRY × erdafitinib × Genitourinary × Clear all

NCT02365597 2026-03-19

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT05316155 2026-03-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05567185 2026-03-13

TAR-210

Phase 1 Active not recruiting

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT06319820 2026-03-13

MoonRISe-1

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03390504 2026-02-02

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03473743 2025-12-23

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Phase 1/2 Active not recruiting

125 enrolled 19 charts

Carcinoma, Transitional Cell

NCT05052372 2022-12-22

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell